van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19:550–61.

Article  PubMed  PubMed Central  Google Scholar 

Chakarun CFD, Gottsegen C, Patel D, White E, Matcuk G. Giant cell tumor of bone: review, mimics, and new developments in treatment. Musculoskelet Imaging. 2013;33:197–211.

Google Scholar 

Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT J. 2017;3:54.

Article  PubMed  PubMed Central  Google Scholar 

Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469:591–9.

Article  PubMed  Google Scholar 

Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev. 2010;36:1–7.

Article  PubMed  Google Scholar 

Anderson WJ, Doyle LA. Updates from the 2020 World Health Organization classification of soft tissue and bone tumours. Histopathology. 2021;78:644–57.

Article  PubMed  Google Scholar 

Cleven AHS, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen A, Bove´e J. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39:1576–83.

Article  PubMed  Google Scholar 

Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology. 2018;72:914–22.

Article  PubMed  Google Scholar 

Forsyth RG, Krenacs T, Athanasou N, Hogendoorn PCW. Cell biology of giant cell tumour of bone: crosstalk between m/wt nucleosome H3.3, telomeres and osteoclastogenesis. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13205119.

Article  PubMed  PubMed Central  Google Scholar 

Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Hum Cell. 2020;33:1321–8.

Article  CAS  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, et al. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Hum Cell. 2022;35:392–9.

Article  CAS  PubMed  Google Scholar 

Akiyama T, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-GCTB5-C1: A novel cell line of giant cell tumor of bone. Hum Cell. 2022;35:1621–9.

Article  CAS  PubMed  Google Scholar 

Adachi Y, Ono T, Noguchi R, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB11-C1 and NCC-GCTB12-C1. Hum Cell. 2025;38:128.

Article  CAS  PubMed  Google Scholar 

Iwata S, Ono T, Noguchi R, et al. Establishment and characterization of NCC-GCTB14-C1 and NCC-GCTB15-C1: Two novel patient-derived cell lines of giant cell tumor of bone. Hum Cell. 2024;38:20.

Article  PubMed  Google Scholar 

Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

Article  PubMed  PubMed Central  Google Scholar 

Kondo T. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 2021;112:953–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dinic J, JovanovicStojanov S, Dragoj M, Grozdanic M, Podolski-Renic A, Pesic M. Cancer patient-derived cell-based models: applications and challenges in functional precision medicine. Life (Basel). 2024;14:1142.

CAS  PubMed  PubMed Central  Google Scholar 

Sobti A, Agrawal P, Agarwala S, M. A. Giant cell tumor of bone - an overview. Arch Bone Jt Surg. 2016;4:2–9.

PubMed  PubMed Central  Google Scholar 

Ogura K, Hosoda F, Nakamura H, et al. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone. Genes Chromosomes Cancer. 2017;56:711–8.

Article  CAS  PubMed  Google Scholar 

Jain SU, Khazaei S, Marchione DM, et al. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proc Natl Acad Sci U S A. 2020;117:27354–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A. 2001;98:8012–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanabe H, Takada Y, Minegishi D, Kurematsu M, Masui T, Mizusawa H. Cell line individualization by STR multiplex system in the cell bank found cross-contamination between ECV304 and EJ-1/T24. Tiss Cult Res Commun. 1999;18:329–38.

Google Scholar 

Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: Where do we draw the line? Int J Cancer. 2013;132:2510–9.

Article  CAS  PubMed  Google Scholar 

Khazaei S, De Jay N, Deshmukh S, et al. H3.3 G34W promotes growth and impedes differentiation of osteoblast-like mesenchymal progenitors in giant cell tumor of bone. Cancer Discov. 2020;10:1968–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Mouradov D, Wang X, et al. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology. 2017;153:1082–95.

Article  PubMed  PubMed Central  Google Scholar 

Sinha R, Luna A, Schultz N, Sander C. A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles. Cell Rep Methods. 2021;1:100039.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang G, Zhang S, Yazdanparast A, et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016. https://doi.org/10.1186/s12864-016-2911-z.

Article  PubMed  PubMed Central  Google Scholar 

Fang L, Liu YJ, Zhang YW, et al. Comparison of proteomics profiles between xenografts derived from cell lines and primary tumors of thyroid carcinoma. J Cancer. 2021;12:1978–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105:452–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer. 2006;5:55.

Article  PubMed  PubMed Central  Google Scholar 

Pipiya VV, Gilazieva ZE, Issa SS, Rizvanov AA, Solovyeva VV. Comparison of primary and passaged tumor cell cultures and their application in personalized medicine. Explor Target Antitumor Ther. 2024;5:581–99.

Article  CAS  PubMed